Holen Sie sich die Stockscreener-App
39.92
0.20%
-0.08
Handel nachbörslich:
39.92
Schlusskurs vom Vortag:
$40.00
Offen:
$40.09
24-Stunden-Volumen:
429.79K
Relative Volume:
0.73
Marktkapitalisierung:
$2.31B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.5141
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+1.76%
1M Leistung:
+16.01%
6M Leistung:
+20.13%
1J Leistung:
-14.35%
1-Tages-Spanne:
$39.65
$40.60
1-Wochen-Bereich:
$38.70
$41.19
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
39.92 | 2.27B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Is Agios Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
Agios Pharmaceuticals Inc. Stock Analysis and ForecastTurbocharged investment results - jammulinksnews.com
What drives Agios Pharmaceuticals Inc. stock priceHigh-yield growth strategies - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockSuperior stock growth - Autocar Professional
What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser
Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser
Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser
Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq
Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan
Public market insider buying at Extendicare (EXE) - The Globe and Mail
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World
FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Trend Tracker for (AGIO) - news.stocktradersdaily.com
Agios pharma chief medical officer Gheuens sells $452,601 in stock By Investing.com - Investing.com Canada
Agios Pharmaceuticals Inc. (AGIO) Shares Soar 7.69% on FDA Designation - AInvest
Agios Pharma Appoints Dr. Jay Backstrom as Director - The Globe and Mail
Agios Pharmaceuticals appoints Jay Backstrom to board of directors By Investing.com - Investing.com South Africa
Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors. - AInvest
Agios Appoints Dr. Jay Backstrom To Board - citybiz
Agios appoints Dr. Jay Backstrom to board of directors - MarketScreener
Agios Appoints Dr. Jay Backstrom to Board of Directors - The Manila Times
Agios Pharmaceuticals Appoints Dr. Jay Backstrom to Board of Directors - Quiver Quantitative
Agios Appoints Dr. Jay Backstrom to Board of Directors | AGIO St - GuruFocus
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Defensive Index - MarketScreener
Agios pharma chief legal officer Burns sells $93k in stock - Investing.com
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN
Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks
Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
TD Cowen reiterates buy rating on Agios stock ahead of key trial data - Investing.com Canada
Agios Pharmaceuticals Sees Shift in Fund Positioning Russell 1000 - Kalkine Media
Cantor Fitzgerald Predicts AGIO FY2026 Earnings - Defense World
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Agios Pharmaceuticals: A More Compelling Valuation (NASDAQ:AGIO) - Seeking Alpha
Avanzanite annuncia la partnership paneuropea con Agios per lanciare mitapivat nelle malattie ematologiche rare - standard-journal.com
Avanzanite annonce un partenariat paneuropéen avec Agios pour le lancement de PYRUKYND® dans les maladies rares du sang - Eagle-Tribune
Avanzanite gibt europaweite Partnerschaft mit Agios zur Einführung von PYRUKYND® bei seltenen Blutgerinnungsstörungen bekannt - standard-journal.com
Agios Pharma stock target cut to $56 by H.C. Wainwright - Investing.com Canada
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):